Novo Nordisk stock falls after cautious growth targets

Novo Nordisk stock closed at DKK 260.00 on Nasdaq Copenhagen on September 21, 2026, down 7.65 percent from DKK 281.60. The selloff followed the company capital markets day, where its medium-term growth ambitions drew a negative market response.

Growth targets disappoint investors

According to Reuters on September 23, 2026, Novo Nordisk aims to launch more than five potential blockbuster drugs by 2030 and generate more than DKK 150 billion in risk-adjusted pipeline sales by 2035. The target is intended to offset pressure on the semaglutide franchise as patent protection approaches expiry.

The central concern is the pace of expansion. Novo Nordisk has presented expected revenue growth of about 4 percent a year from 2027 through 2030, while analysts cited by Invezz forecast 2 percent to 3 percent revenue and EBIT growth in 2027. That comparison explains why a large pipeline ambition did not prevent a sharp share-price reaction.

Pipeline must replace semaglutide

According to Reuters on September 22, 2026, Chief Executive Mike Doustdar said oral weight-loss treatments could capture as much as 50 percent of the global obesity-drug market by 2030. The company is therefore positioning tablets as a second growth engine alongside injectable treatments.

The financial base is under pressure. A September 22, 2026 report citing Novo Nordisk's 2026 outlook said adjusted sales growth and adjusted operating-profit growth were expected to range from 0 percent to minus 6 percent at constant exchange rates. The same report said the company recorded a DKK 6.3 billion non-recurring, non-cash pipeline impairment in the second quarter of 2026, including DKK 4.0 billion related to monlunabant.

Stock remains near yearly low

Novo Nordisk stock traded at DKK 257.50 on Nasdaq Copenhagen on September 23, 2026, down 0.50 percent, with volume of 1,291,665 shares. The reported 52-week range was DKK 224.30 to DKK 410.00, placing the price DKK 33.20 above the low and DKK 152.50 below the high.

Deutsche Bank cut its price target from DKK 265 to DKK 245 and retained a Sell rating after the capital markets day, according to AD HOC NEWS on September 23, 2026. MarketScreener showed a consensus of Hold from 25 analysts, with an average target of DKK 307.56 against a last close of DKK 258.80.

Next results are due November 3

The next quarterly results are scheduled for November 3, 2026, according to the company calendar data carried by MarketScreener. That report will provide the next scheduled test of the 0 percent to minus 6 percent full-year outlook and the pipeline strategy.

More news and analyses on Novo Nordisk stock